NutriBand Inc.NTRB

NutriBand Inc. lost $1.2 million in the three months to 30 April 2026 on revenue of $433,399, according to its latest 10-Q, while operating cash burned $563,104 and the diluted loss ran to ten cents a share across 12.2 million shares. The cash pile still stands at $4.0 million, but the company’s ability to fund operations from its own cash flow is not yet visible in the filings.

NutriBand calls itself a developer of abuse-deterrent transdermal drug delivery systems and has branded its lead opioid patch programme, an abuse-deterrent fentanyl transdermal system, ahead of a planned FDA submission. Yet the same 10-Q that records the losses shows no revenue tied to that franchise, leaving the core product story hanging on a filing promise rather than a filed payoff.

The quarter’s filing also shows four customers supplying about 69% of total revenue, with the top buyer accounting for roughly a quarter, underscoring the thin base beneath the company’s broader ambitions. Research and development ran at $247,261, while capital spending on property, plant and equipment was a modest $5,324. Inventory crept up by only $3,507, and liabilities remained light at $902,312 against $6.0 million of shareholders’ equity.

The operating loss was $1.3 million in the quarter, and the company’s cash used in operating activities was $563,104, all of which frames the gap between the polished AI wellness and abuse-deterrent narratives and the balance sheet’s actual receipts. (source: NTRB 10-Q (2026-06-11), https://www.sec.gov/Archives/edgar/data/1676047/000121390026067840/ea0294013-10q_nutriband.htm)

The company’s Active Intelligence unit is set to showcase an expanding AI wellness product portfolio and new June product launches at an ECRM conference, with product images and retailer meetings planned with Walmart, Walgreens, Amazon and Cardinal Health. These items appear on the company’s news site and product pages but are not reflected in the latest quarterly revenue or cash-flow lines. (source: Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference, https://www.nutriband.com/post/nutriband-inc-to-showcase-expanding-ai-wellness-product-portfolio-and-new-june-product-launches-at-e)

The company also announced an exclusive distribution agreement in March 2026 with Innomedica CCB S.A. covering its Kinesiology Line, AVERSA products and mosquito repellent patches, but the 10-Q does not quantify any revenue impact from that deal. (source: Nutriband Newsroom - Latest Press Releases and Announcements, https://www.nutriband.com/news)

The SEC filings index and the company’s investor-relations pages point to the formal disclosures, but the current documents do not include segment-level breakouts, forward guidance or quantified milestone payments tied to the FDA submission or distribution deals. (source: SEC Reports & Filings | Nutriband - Financial and Compliance Info, https://www.nutriband.com/filings; Nutriband Investor Relations - Stock Info & Financial Reports, https://www.nutriband.com/investors)